| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Medicine and Pathology, University of California, San Diego, and the Infectious Diseases Section, VA Medical Center, San Diego, CA.
Address correspondence and reprint requests to Dr. Michael N. Oxman, Infectious Diseases Section (111F), VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161.
Herpes zoster (HZ) is a localized disease that results from reactivation of an endogenous varicella-zoster virus (VZV) infection that has persisted in latent form within sensory ganglia following an earlier attack of varicella. The incidence and the severity of HZ and its complications increase with advancing age, and this is temporally associated with an age-related decline in cell-mediated immunity (CMI) to VZV. Information on the cellular site and mechanism of VZV latency and on the events that follow reactivation appears to explain many of the clinical features of HZ and to provide a pathophysiologic basis for the presumption that immunity to VZV plays a critical role in limiting the frequency and consequences of VZV reactivation. The close temporal correlation between the decline in VZV-specific CMI and the increased frequency and severity of HZ and its complications in older individuals suggests that HZ may actually develop because VZV-specific CMI falls below some critical threshold. The development of a live attenuated varicella vaccine provides a means of stimulating VZV-specific CMI and thus of determining its role in the pathogenesis of HZ. Levin and his colleagues have demonstrated that waning VZV-specific CMI in elderly persons can be stimulated by varicella vaccine to levels typical of those observed in younger persons, in whom the incidence and severity of HZ are much reduced. Thus the stage is set for a large placebo-controlled clinical trial that will test directly the hypothesis that restoration of waning CMI to VZV will reduce the frequency and severity of HZ and its complications in the elderly.
NEUROLOGY 1995;45(Suppl 8): S41-S46
This article has been cited by other articles:
|
|
 |
|
  R. J. Whitley A 70-Year-Old Woman With Shingles: Review of Herpes Zoster JAMA, July 1, 2009; 302(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Oxman Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence J Am Osteopath Assoc, June 1, 2009; 109(6_suppl_2): S13 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Kimberlin and R. J. Whitley Varicella-Zoster Vaccine for the Prevention of Herpes Zoster N. Engl. J. Med., March 29, 2007; 356(13): 1338 - 1343. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Burke Herpes Zoster Vaccine: Clinical Trial Evidence and Implications for Medical Practice J Am Osteopath Assoc, March 1, 2007; 107(suppl_1): S14 - S18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hornberger and K. Robertus Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med, September 5, 2006; 145(5): 317 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Goldman Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster International Journal of Toxicology, July 1, 2005; 24(4): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, L.D. Gelb, R.D. Arbeit, M.S. Simberkoff, A.A. Gershon, L.E. Davis, et al. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults N. Engl. J. Med., June 2, 2005; 352(22): 2271 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Irwin, J. Pike, and M. Oxman Shingles Immunity and Health Functioning in the Elderly: Tai Chi Chih as a Behavioral Treatment Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Gnann Jr. and R. J. Whitley Herpes Zoster N. Engl. J. Med., August 1, 2002; 347(5): 340 - 346. [Full Text] [PDF]
|
|
|
|
 |
|
 J Breuer Vaccination to prevent varicella and shingles J. Clin. Pathol., October 1, 2001; 54(10): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Déry, W. Vaudry, E. Mills, S. Halperin, A. Michaliszyn, and M. Rivière Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases Pediatrics, July 1, 1999; 104(1): 1 - 6. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. G. Kost and S. E. Straus Postherpetic Neuralgia: Predicting and Preventing Risk Arch Intern Med, June 9, 1997; 157(11): 1166 - 1167. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
